Sovaldi makes blockbuster history, ignites drug pricing unrest
Sovaldi makes blockbuster history, ignites drug pricing unrest
复制标题
Sovaldi 创造重磅历史，引发药品定价动荡
DOI：
--
复制
发表时间：
2014
影响因子：
46.9
通讯作者：
Melanie R Senior
中科院分区：
文献类型：
--
作者：
Melanie R Senior
美国最大的健康保险公司，在Sovaldi上市的前3个月就花了1亿美元，是预期的数倍，尽管部分原因是被压抑的需求。付款人可以通过只允许病情最严重的患者使用Sovaldi来限制摄入量，例如患有肝纤维化或处于肝移植边缘的患者。瑞士信贷（Credit Suisse）驻纽约的生物技术分析师拉维？梅赫罗特拉（Ravi Mehrotra）表示："付款人可能比以往更具侵略性，例如在分层和偏好方面。"有些是其他人，包括康涅狄格州哈特福德的安泰制药政策和战略副总裁Edmund Pezalla，正在"检查建立良好临床实践的证据"。大多数付款人不希望被视为拒绝创新治疗他们的成员，并捆绑医生的双手背后，没有至少一些临床理由这样做。迈克尔谢尔曼，高级副总裁兼首席医疗官在波士顿的付款人哈佛朝圣者医疗保健将欢迎客观，实用的指导方针，从相关协会的医疗Sovaldi制造重磅炸弹的历史，点燃药品定价动荡
largest US health insurer, spent $100 million on Sovaldi in its first 3 months on the market—a multiple of what it expected, though partly due to pent-up demand. Payers could restrict uptake by allowing only the sickest patients onto Sovaldi, such as those with liver fibrosis or on the brink of a liver transplant. “Payers can be more aggressive than they historically have been, for instance with tiering and preferences,” opines Ravi Mehrotra, biotech analyst at Credit Suisse in New York. Some are. Others, including Edmund Pezalla, vice president, pharmacy policy and strategy, at Hartford, Connecticut–based Aetna, are “examining the evidence as good clinical practice is established.” Most payers don’t want to seen as denying innovative treatments to their members, and as tying physicians’ hands behind their backs, without at least some clinical rationale for doing so. Michael Sherman, senior vice president and chief medical officer at Bostonbased payer Harvard Pilgrim HealthCare would welcome objective, practical guidelines from a relevant association of medical Sovaldi makes blockbuster history, ignites drug pricing unrest